Low Dose Moderna
Gates Package, pp.1198-1200 · gates:email:00781
Page text: p.1198, p.1199, p.1200 · original PDF
- Date
- 2021-07-26 15:23
- Type
- email · email
- sender
- Trevor Mundel
https://www.medrxiv.org/content/10.1101/2021.06.30.21259787v1.full.pdf
Bill, Tony, this is the low (1/4) dose Moderna data which looks quite strong - I know Sette has a lot of additional
data he presented over the weekend and I'm trying to get this from him.
Regulatory authorities (EMA and MHRA thus far) have agreed to immunogenicity phase 3 trials for the new
vaccines coming along due to the inability to do standard phase 3 - in the 2 case I know of the endpoint will be
NA superiority to the AZ vaccine. By this standard we can be sure that Moderna low dose already meets this
standard and of course going with a lower dose of an approved vaccine means that safety issues are off the table.
This is the only pathway to immediately double capacity from Moderna and even if only part of their supply was
allocated to this it could mean a few hundred million additional vaccines in 2021.
Trevor
Get Outlook for iOS
From: Trevor Mundel HR
2 «21s foundation.org>
To: Tony Fauci HEE 2 niaid.nin.gov>
Cc: Christa Bowles HR
6 «21 esfoundation.org>
Subject: Connect with Bill
Date: Tue, 31 Mar 2020 22:02:12 -0400
Importance: Normal
Hi Tony, great work in keeping things on such an even keel. Bill was keen to catch up with you and I wondered
if you might have 30-45 min any time between 5:30pm and 8pm EST tomorrow to chat with him. Regards,
Trevor
Trevor Mundel, MD, PhD
President, Global Health Program
Vv'
E
E
gatesfoundation.org
Christa Bowles
Executive Assistant
Office of the President, Global Health
Vv
M
E
)gatesfoundation.org
Bill & Melinda Gates Foundation
www.gatesfoundation.org
E]"
'les
h Bill
to Tony F but got an
tomorrow
||
>
2 PM
Links shared
- preprint https://www.medrxiv.org/content/10.1101/2021.06.30.21259787v1.full.pdf
- other www.gatesfoundation.org